Daily Stock Analysis, GBT, Global Blood Therapeutics Inc, priceseries

Global Blood Therapeutics Inc. Daily Stock Analysis
Stock Information
Open
56.46
Close
55.42
High
57.02
Low
55.22
Previous Close
56.42
Daily Price Gain
-1.00
YTD High
59.95
YTD High Date
Apr 12, 2019
YTD Low
39.53
YTD Low Date
Jan 3, 2019
YTD Price Change
14.29
YTD Gain
34.74%
52 Week High
59.95
52 Week High Date
Apr 12, 2019
52 Week Low
30.15
52 Week Low Date
Nov 30, 2018
52 Week Price Change
10.82
52 Week Gain
24.26%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Feb 7. 2017
16.80
Mar 29. 2017
37.90
35 Trading Days
125.58%
Link
LONG
Sep 27. 2017
28.50
Oct 19. 2017
31.67
16 Trading Days
11.14%
Link
LONG
Oct 24. 2017
33.20
Nov 10. 2017
38.71
13 Trading Days
16.59%
Link
LONG
Jan 9. 2018
47.15
Jan 31. 2018
58.14
15 Trading Days
23.32%
Link
LONG
Aug 14. 2018
46.40
Aug 29. 2018
49.21
11 Trading Days
6.06%
Link
LONG
Mar 28. 2019
52.00
Apr 15. 2019
57.56
12 Trading Days
10.69%
Link
Company Information
Stock Symbol
GBT
Exchange
NasdaqGS
Company URL
http://www.globalbloodtx.com
Company Phone
650741-7700
CEO
Ted W. Love
Headquarters
California
Business Address
400 EAST JAMIE COURT, SUITE 101, SOUTH SAN FRANCISCO, CA 94080
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0001629137
About

Global Blood Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering, developing and commercializing novel therapeutics to treat grievous blood-based disorders. It also provides oral medicines for sickle cell diseases. The company was founded by Matthew P. Jacobson, Andrej Sali, Jack Taunton, Charles J. Homcy, Craig D. Muir and David R. Phillips in February 2011 and is headquartered in South San Francisco, CA.

Description

Global Blood Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel therapeutics to treat grievous blood-based disorders. Its lead product candidate is GBT440, a hemoglobin modifier that binds to hemoglobin molecules, which is in Phase 3 clinical trial for the treatment of sickle cell disease (SCD) in adult and adolescent patients, as well as evaluates the safety and pharmacokinetics of single and multiple doses of GBT440 on adolescent patients with SCD. The company is also involved in conducting Phase 2 clinical trials of GBT440 for the treatment of idiopathic pulmonary fibrosis, which is a hypoxemic pulmonary disorder; and other pre-clinical research and development activities. Global Blood Therapeutics Inc. was founded in 2011 and is headquartered in South San Francisco, California.